

Freedom of Information Act Disclosure log - Reply Extract

| | |
|------------------------|---|
| File reference | W21FOI205 |
| Key words | Treatment of Oesophageal and Gastric Cancer |
| Date of release | 13/08/2021 |
| Attachments | No |

You asked

1. Does your trust treat the following conditions?

- Advanced oesophageal cancer = Yes
- Advanced gastric cancer = Yes
- In case you do not treat either of the above conditions, which other trust do you refer these patients to? N/A

2. Please provide the total number of patients treated in the last 6 months for:

Please note that the Trust can only provide the number of patients that *started* treatment at Derriford between 1st January 2021 – 30th June 2021. This information is as follows:

- Oesophageal cancer (any type) = 103
- Oesophageal adenocarcinoma = 73
- Oesophageal squamous cell carcinoma = 13
- Unresectable oesophageal squamous cell carcinoma = *Please see below
- Gastric cancer (any type) = 34
- HER2 negative or HER2 untested gastric cancer = *Please see below

*The Trust does not hold this information in an electronic searchable format. This information will be recorded in paper based clinical records, but the Trust could not locate, extract and collate such information as requested within the limitations of the Act. Please refer to the legal notes below.

3. For oesophageal squamous cell carcinoma only, how many patients were treated in the past 6 months with: Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)

We used SACT data 1/1/21 – 30/6/21 and ICD codes C15 – C15.9 (oesophagus – unable to differentiate just the SCC oesophageal patients) to identify those patients that have had a cycle prescribed during this time.

Capecitabine & Carboplatin = Five or fewer

Capecitabine & Cisplatin = Five or fewer

ECX = Five or fewer

EOX = 13

FLO = Five or fewer

FLOT = 9

HCX Ontruzant (biosimilar trastuzumab) =

Five or fewer

XEOLX = 7

- **Any other systemic anti-cancer therapy**

Carboplatin & Etoposide = Five or fewer

Carboplatin & Paclitaxel = Five or fewer

Docetaxel = Five or fewer

Irinotecan = Five or fewer

Palliative care only = 0

4. For gastric cancer only, how many patients were treated in the past 6 months with:

We used SACT data 1/1/21 – 30/6/21 and ICD codes C16 – C16.9 (stomach) and D37.1 (neoplasm of uncertain or unknown behaviour of stomach) to identify those patients that have had a cycle prescribed during this time

- CapeOx (Capecitabine with Oxaliplatin) = Five or fewer

Oxalicap = Five or fewer

- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)

- Any other systemic anti-cancer therapy

Capecitabine & irinotecan = Five or fewer

Capecitabine = Five or fewer

Docetaxel = Five or fewer

ECX = Five or fewer

EOX = Five or fewer

FLO = Five or fewer

FLOT = Five or fewer

HOX Ontruzant (biosimilar trastuzumab) = Five or fewer

Irinotecan = Five or fewer

Paclitaxel = Five or fewer

XELOX = Five or fewer

- Palliative care only = Five or fewer

5. Does your trust participate in any ongoing clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.

The Trust completes a non-disclosure agreement when it participates in clinical trials because the information is commercially sensitive. The Trust would breach the conditions of any agreement and reveal commercially sensitive information if it were to provide an answer to this question. This would constitute a breach of confidence that would be actionable in court by that or any other person. The Trust is declining to supply the information in compliance with section 41.-(2).

6. Does your trust participate in any ongoing clinical trials for the treatment of gastric cancer? If so, can you please provide the name of each trial and the number of patients taking part.

As per our response to Q5.

Legal notes:

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b), unless otherwise specified below and for that reason

It constitutes personal information.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. Figures of five or fewer are considered personally identifiable information. Our approach avoids a breach of the first two Data Protection Act principles and the general right to object to processing, whilst providing you with as much detail as possible. This is in accordance with section 40.(2)(a) and (b) by virtue of the first and second condition.

The information is or would be provided in confidence as part of a non-disclosure agreement because it or would be commercially sensitive.

Section 41 can apply if

- it was obtained by the authority from any other person,
- its disclosure would constitute a breach of confidence.
- a legal person could bring a court action for that breach of confidence, and
- that court action would be likely to succeed

Section 41(2) provides an exclusion from the duty to confirm or deny whether information is held. This exclusion applies if confirming or denying that information is held would in itself give rise to a breach of confidence, actionable by any person, that would be likely to succeed.

Section 43 the commercial Interest exemption has not been applied because we are relying on section 41 however at review any review should consider the use of section 43(2 and 3)

Attachments included: No